Neurotensin receptors in pancreatic ductal carcinomas. by Körner Jachertz, Meike et al.
Körner et al. EJNMMI Research  (2015) 5:17 
DOI 10.1186/s13550-015-0094-2
s
o
u
r
c
e
:
 
ht
tp
s:
//
do
i.
or
g/
10
.7
89
2/
bo
ri
s.
70
21
1 
| 
do
wn
lo
ad
ed
: 
13
.3
.2
01
7ORIGINAL RESEARCH Open AccessNeurotensin receptors in pancreatic ductal
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Meike Körner1, Beatrice Waser1, Oliver Strobel2, Markus Büchler2 and Jean Claude Reubi1*Abstract
Background: The frequent expression of neurotensin receptors (NT-R) in primaries of pancreatic ductal carcinomas
has triggered the development of radioactive neurotensin analogs for possible in vivo targeting of these tumors.
However, the complete lack of information regarding NT-R in liver metastases of pancreatic cancer and pancreatic
intraepithelial neoplasia (PanIN) makes an in vitro study of NT-R in these tissues indispensable.
Methods: Using in vitro receptor autoradiography with 125I-[Tyr3]-neurotensin, NT-R were investigated in 18 primaries
and 23 liver metastases of pancreatic ductal carcinomas as well as in 19 PanIN lesions.
Results: We report here that 13 of 18 ductal carcinoma primaries and 14 of 23 liver metastases expressed NT-R.
Moreover, none of the six PanIN 1B cases expressed NT-R, while two of six PanIN 2 and five of seven PanIN 3
expressed NT-R. Binding was fully displaced by the type 1 NT-R-selective antagonist SR48692, indicating that the
NT-R in the tumors are of the type 1 NT-R subtype.
Conclusions: These in vitro data extend the currently available information on NT-R in invasive and non-invasive
pancreatic ductal tumors. They suggest that type 1 NT-R may be a novel, specific marker of PanIN of higher degree.
The high expression of NT-R in primaries and metastases of invasive cancer strongly support the need to develop
radioactive neurotensin analogs for the diagnosis and therapy of this tumor type.
Keywords: Neurotensin receptors; Pancreatic ductal carcinomas; Liver metastasis; Pancreatic intraepithelial
neoplasia; Tumor imagingBackground
Two decades ago, neurotensin receptors (NT-R) were
found to be expressed in approximately 75% of primary
pancreatic ductal adenocarcinomas by NT-R autoradiog-
raphy [1]. The NT-R were present in high density in the
tumor cells, while the non-neoplastic pancreatic ducts
did not express NT-R [1]. This suggested for the first
time the possibility to specifically target pancreatic
tumor cells via NT-R [1]. These expression data were
confirmed by Ehlers et al. showing an approximately
90% incidence of NT-R in pancreatic cancers by RT-PCR
measurement [2]. Later on, several groups identified NT-
R in various other cancer types [3-7]. The role and func-
tion of the NT-R in cancer has also been investigated in
the past one to two decades [8,9]. It appears to be clear
that NT-R (especially the type 1 NT-R (also named NTS1* Correspondence: jean.reubi@pathology.unibe.ch
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in any medium, provided the original work is p[10])) mediate a proliferative action of neurotensin in pan-
creatic cancer and also in other tumors [9,11-14]. There is
also strong evidence that the type 1 NT-R-selective antag-
onist SR48692 [15] can inhibit tumoral proliferation
[12-14]. Therefore, the use of neurotensin analogs has been
proposed as strategy for the antiproliferative treatment of
pancreatic cancer [3,8,16,17].
On the other hand, these in vitro receptor expression
data [1,2] also triggered the development of radioactive
neurotensin analogs that could be used for the visualization
and, eventually, targeted radiotherapy of pancreatic ductal
adenocarcinoma and other tumors. The majority of the
published compounds are radiolabeled NT-R agonists
[18-24], but radiolabeled NT-R antagonists have recently
appeared [25,26]. Proof of principle that pancreatic ductal
carcinomas can be visualized in patients with radiolabeled
NT-R agonists was provided in preliminary studies
[27-29]. Indeed, it would be important to have a reliable
non-invasive tool permitting to visualize the majority ofn Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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equally important to be able to treat the patients that have
a receptor-positive carcinoma by giving them a radio-
therapeutic dose of the radiolabeled neurotensin; many of
the patients diagnosed with pancreatic ductal carcinomas
already have or will soon have metastatic disease. Most
patients die due to systemic disease within a short period
of time after resection [30].
A targeted therapy of pancreatic cancer would, how-
ever, make sense only if all tumor manifestations in a
given patient, namely the primary and the metastases,
express NT-R. Considering the frequent observation of
tumor heterogeneity in cancer in general, in terms of
both histopathological features and of biological parame-
ters, it is not possible to simply extrapolate that NT-R-
positive primary pancreatic ductal carcinomas will give
rise to NT-R-positive metastases. Unfortunately, there
are presently no experimental data indicating whether
metastases of ductal pancreatic carcinomas express NT-
R. This lack of information is due in part to the fact that
these metastases are not operated and that metastasis
material is hardly available for in vitro investigations. In
the present study, we have been able to investigate a sig-
nificant number of metastases of ductal pancreatic car-
cinomas, sometimes together with their primaries, using
NT-R autoradiography. To complete the study, we have
also investigated NT-R in non-invasive, intraductal neo-
plasia (PanIN) using the same methodology.
Methods
Tissues
Pancreatic ductal carcinoma samples were collected at
the Department of General, Visceral and Transplantation
Surgery, University Hospital Heidelberg, Heidelberg,
Germany, and at the Institute of Pathology, University of
Bern, Bern, Switzerland. The number and types of tis-
sues investigated are listed in Tables 1 and 2. All tissues
were frozen in liquid nitrogen or in dry ice immediately
after surgical resection and stored at −70°C. Informed
consent was available for all patients. The study collec-
tion conformed to the ethical guidelines of both centers
and was reviewed by the Institutional Review Boards of
University Hospital Heidelberg and University of Bern.
NT-R autoradiography
Receptor autoradiography was performed on 20-μm-thick
cryostat (Microm HM550, Thermo Fisher Scientific,
Walldorf, Germany) sections of the tissue samples,
mounted on microscopic slides and then stored at −20°C
for at least 3 days to improve adhesion of the tissue to the
slide. Sections were pre-incubated in 50 mM Tris–HCl
pH 7.4 with 0.02% BSA for 3 times at 5 min at 20°C. Slides
were then incubated in 50 mM Tris–HCl pH 7.4 contain-
ing 0.02% BSA, 1 mM o-phenantroline, 1 mM MgCl2 and40,000 dpm/100 μl (corresponding to 90 pM) 125I-[Tyr 3]-
Neurotensin (2,000 Ci/mmol; ANAWA, Wangen,
Switzerland) for 1 h at room temperature. Additional
sections were incubated in the presence of 100 nM non-
radioactive neurotensin (Bachem, Bubendorf, Switzerland)
to assess non-specific binding, as well as in the presence
of 1,000 nM of the type 1 NT-R-selective analog SR48692
(Sanofi, Paris, France), for NT-R subtyping. After incuba-
tion, the slides were washed for 10 min at 4 °C in four
consecutive baths containing 50 mM Tris–HCl pH 7.4
with 0.02% BSA. After a brief dip in buffer without BSA,
the sections were dried under a stream of cold air and
then exposed to Kodak (Rochester, NY, USA) films
Biomax MR for 7 days at 4 °C. The autoradiograms
were quantified using a computer-assisted image pro-
cessing system (Analysis Imaging System, InterFocus,
Mering, Germany). Tissue standards for iodinated
compounds (Amersham, Aylesbury, UK) were used for
this purpose [1,4].
Results and discussion
Table 1 summarizes the data of NT-R incidence and
density in pancreatic ductal carcinoma patients. The
results are divided into three groups, depending on the
availability of the respective frozen tissue: (1) primaries
only, (2) primary and liver metastasis of the same pa-
tient, and (3) metastases only. It can be seen that not
only primaries do often express NT-R in high density
but also the liver metastases. The overall incidences of
NT-R expression are 73% (8 of 11 cases) in primaries
and 63% (14 of 23 cases) in metastases. Interestingly, all
NT-R-expressing tumors have a high receptor density,
namely above 3,000 dpm/mg tissue. From the six pa-
tients of whom primary and metastasis are available,
three have high NT-R expression in both primary and
metastasis, two have high expression in the primary
only, and one is receptor-negative in both. This latter
case had chemotherapy (gemcitabine) prior to the surgi-
cal resection. It cannot, however, be concluded definitely
that chemotherapy is responsible for the lack of NT-R,
since another chemotherapy-treated patient (Table 1)
had a high NT-R expression over 6,000 dpm/mg tissue
in his tumor. As also stated in Table 1, we have also
performed displacement experiments with incubation
of the 125I-[Tyr3]-neurotensin radioligand in the pres-
ence of 1,000 nM of the cold type 1 NT-R-selective
analog SR48692. In the tested cases listed in Table 1,
radioligand binding could be completely displaced by
SR48692 indicating the presence of the type 1 NT-R
subtype in these tissues. Three tumors (No. 11, 26, 27)
could not be tested for SR48692 due to lack of tissue.
Figure 1 illustrates a case of a patient with high NT-R
expression in both the primary and the liver metasta-
sis. Here, the NT-R are densely and homogeneously
Table 1 NT receptors in ductal pancreatic cancer primaries and liver metastases
Patient number Primary Metastasis Comments
Receptor density dpm/mg tissue Receptor density dpm/mg tissue
Primary only
1 8,335 (9,392; 7,278)a
2 0
3 0
4 6,194 (6,317; 6,071) heta
5 9,600 (9,301; 9,899)a
Primary + metastasis of same patient
6 9,310 (9,157; 9,462) heta 0
7 3,053 (2,953; 3,152) heta 3,982 (4,584; 3,379) heta
8 10,274 (10,626; 9,921)a 5,084 (5,174; 4,993) heta
9 0 0 Chemotherapy before resection
10 6,026 (6,243; 5,808)a 0
11 6,145 (6,405; 5,884) 4,482 (4,978; 3,986)
Metastasis only
12 10,866 (11,013; 10,719)a
13 8,611 (8,189; 9,033)a
14 8,517 (8,791; 8,243)a
15 0
16 0
17 6,124 (6,075; 6,172) heta Chemotherapy before resection
18 13,207 (13,169; 13,245)a
19 13,235 (13,047; 13,422)a
20 9,753 (9,872; 9,634)a
21 0
22 6,842 (8,250; 5,433)a
23 10,684 (12,298; 9,070)a
24 0
25 0
26 7,671 (7,259; 8,083)
27 7,828 (7,959; 7,697)
28 0
Mean ± SEM of positive cancers 7,367 ± 860 8,349 ± 791
Total incidence 8/11 (73%) 14/23 (61%)
het, heterogeneous NT-R distribution. Values represent NT-R density (dpm per mg tissue) as mean of two separate experiments with individual values in parenthesis.
aIn addition to the displacement by neurotensin, full displacement by SR48692 was observed in these tumors.
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normal pancreas and liver, respectively, are NT-R-
negative.
Table 2 shows samples of additional pancreatic ductal
tumor patients with resected pancreatic tissue contain-
ing various stages of PanIN with or without the corre-
sponding invasive ductal carcinoma. Here, there is a
clear difference in NT-R expression depending on the
PanIN stage: None of the six PanIN 1B cases expresses
NT-R, and only two out of the six PanIN 2 cases expressNT-R, whereas the majority of the PanIN 3 cases (five
out of seven cases) express NT-R. Interesting is the ob-
servation that in the two latter NT-R-negative PanIN 3
patients, their corresponding invasive ductal carcinomas
(and their PanIN 1B and 2 stages as well) are also NT-R-
negative. In three other cases, we see the NT-R
expressed in PanIN 3 stages as well as in invasive ductal
carcinomas, while adjacent PanIN 1B and/or PanIN 2
stages in these patients are NT-R-negative. Figure 2
illustrates the NT-R status in various PanIN lesions.
Table 2 Quantification of NT-R in PanIN 1B, 2, and 3 and in concomitant invasive pancreatic carcinoma
Patient number PanIN 1B PanIN 2 PanIN 3 Invasive ductal carcinomab
29 - 1,882 (1,732;1,923)a - -
30 - - 5,809 (5,937;5,681)a 1,257 (1,290;1,223)a
31 0 - - -
32 0 0 0 0
33 - >10,000 (>10,000;>10,000)a 9,871 (9,741;10,000)a 8,769 (8,885;8,652)a
34 0 - 1,937 (1,881;1,992)a 1,651 (1,759;1,542)a
35 - 0 3,103 (3,209;2,996)a 2,539 (2,771;2,306)a
36 0 0 - -
37 0 - 9,988 (9,976;10,000)a >10,000 (>10,000;>10,000)a
38 0 0 0 0
Mean ± SEM of positive cases 0 5,914 ± 4,086 6,142 ± 1,669 4,843 ± 1,876
Values represent neurotensin receptor density (dpm/mg tissue). aIn addition to the displacement by neurotensin, full displacement by SR48692 was observed in
these tissues. bThese cases are different from those listed in Table 1. Hyphen (−) means no corresponding tissue available.
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expressing PanIN 2 and PanIN 3 and invasive ductal cancer
cases displacement experiments with incubation of the 125I-
[Tyr3]-neurotensin radioligand in presence of 1,000 nM of
the cold type 1 NT-R-selective analog SR48692. In all
cases, radioligand binding could be completely displaced
by SR48692, reaching low binding levels corresponding to
non-specific binding, similar to that identified in theA B
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Figure 1 Expression of NT-R by in vitro receptor autoradiography. NT
metastasis (D-F). As negative control, a NT-R-negative liver metastasis is also sho
tissue (Tu) and the adjacent pancreas (P) or liver (L), respectively. Bars = 1 mm
High density of NT-R is found in the tumors but not in the pancreas or liver. (H
lacks NT-R. (C), (F), (I) Autoradiograms showing non-specific binding of 125I-[Tpresence of 100 nM cold neurotensin. This is illustrated in
Figure 3 for a PanIN 3 lesion and an adenocarcinoma.
This set of experiments indicates that the NT-R in these
tissues are of the type 1 subtype.
This study confirms on the one hand that pancreatic
ductal cancers frequently express a high density of NT-R,
as reported previously [1,2]. However, it expands this
information in two ways: (1) it clearly shows that liverC
F
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-R expressed in a ductal pancreatic carcinoma: primary (A-C) and liver
wn (G-I). (A), (D), (G) Hematoxylin-eosin-stained sections showing tumor
. (B), (E) Autoradiograms showing total binding of 125I-[Tyr3]-neurotensin.
) Autoradiogram showing total binding of 125I-neurotensin. This metastasis
yr3]-neurotensin (in the presence of 100 nM neurotensin).
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Figure 2 NT-R in vitro receptor autoradiography in PanIN. In vitro receptor autoradiography of NT-R in various PanIN, PanIN 1B (A-C), PanIN 2
(D-F), and PanIN 3 (G-I), and in invasive cancer (J-L). (A), (D), (G), (J) Hematoxylin-eosin-stained sections (bars = 0.1 mm), including insert of
representative area at high magnification. (B), (E), (H), (K) Autoradiograms showing total binding of 125I-[Tyr3]-neurotensin. While the PanIN 1 case
(B) is NT-R-negative, PanIN 2 (E), PanIN 3 (H), and invasive cancer (K) are NT-R-positive. (C), (F), (I), (L) Autoradiograms showing non-specific
binding of 125I-[Tyr3]-neurotensin (in the presence of 100 nM neurotensin).
A B C D
E F G H
Figure 3 Autoradiography of NT-R and competition by SR48692. NT-R autoradiography of PanIN 3 (A-D) and of an adenocarcinoma (E-H)
with neurotensin and the type 1 NT-R-selective SR48692 as displacer. (A), (E) Hematoxylin-eosin-stained sections (bars = 0.1 mm). (B), (F) Autoradiograms
showing total binding of 125I-[Tyr3]-neurotensin. (C), (G) Autoradiograms showing non-specific binding (in the presence of 100 nM neurotensin).
(D), (H) Autoradiograms showing full displacement of 125I-[Tyr3]-neurotensin binding in the presence of 1,000 nM SR48692. The detected NT-R
are therefore the type 1 NT-R.
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It thus closes an information gap and has clinical signi-
ficance: indeed, the current knowledge of a NT-R expres-
sion solely in primaries would not be sufficient to
legitimate NT-R targeted diagnostic or therapeutic inter-
ventions, since many of ductal pancreatic patients have
metastases at the time of diagnosis. (2) The study also pro-
vides novel information on NT-R expression in putative
pancreatic cancer precursor lesions, namely PanIN. It sug-
gests an increase in NT-R expression from PanIN 1B to
PanIN 3, with PanIN 1B completely lacking NT-R, as it is
the case for normal pancreatic ducts [1], while PanIN 3
frequently expresses NT-R in high amounts. It is further of
interest that in cases with NT-R-expressing PanIN 3,
accompanying primary carcinomas also express NT-R, in
line with the concomitant expression of many other bio-
logic markers in high-grade PanIN and invasive cancer.
Therefore, NT-R, in particular the type 1 NT-R detected
in this study, may be considered as a novel, specific marker
of pancreatic intraepithelial neoplasia of higher degree.
These data may have potential clinical implications.
Indeed, knowing that NT stimulates pancreatic tumor
growth [11,13,14] and that the type 1 NT-R-selective an-
tagonist SR48692 inhibits tumor cell proliferation [13], it
could be speculated that type 1 NT-R antagonists may
be used for treatment of pancreatic cancer primaries,
but also of their liver metastases and, speculatively, of
the putative cancer precursors, the NT-R-expressing
PanIN 2 and 3.
The data may also have more immediate diagnostic and
radiotherapeutic implications. There are several newly
designed neurotensin analogs which can be labeled with
radioactive compounds [18,20,21,23] and that can be
used either for SPECT or for PET diagnostic evaluation.
Preliminary clinical evaluation was performed with two of
them, however, with limited success probably due to rapid
degradation of the tracers [27,28]. Recently, in line with
the observation that somatostatin and bombesin receptor
antagonists may be advantageous for tumor radiotargeting
[31-34], radiolabeled NT-R antagonists have been devel-
oped aimed at greater metabolic stability, less side effects
than agonists, and increased tumor uptake compared with
agonists [25,26,29]. Such radioactive neurotensin analogs
may become useful as diagnostics for the visualization of
primary pancreatic carcinoma and their metastases and
therefore help to decide on the therapeutic strategy. These
radiolabeled neurotensin analogs may also be used for
targeted radiotherapy of primaries and metastases, in
particular since the NT-R expression is often very high.
Moreover, at the same time, the putative precursor lesions,
the NT-R-expressing PanIN 2 and PanIN 3, may also
be destroyed. The amount of NT-R expressed in all
these lesions appears clearly high enough for such a
clinical application.Conclusions
These in vitro data extend the currently available infor-
mation on NT-R in invasive and non-invasive pancreatic
ductal tumors. They suggest that type 1 NT-R may be a
novel, specific marker of PanIN of higher degree. The
high expression of NT-R in primaries and metastases of
invasive cancer strongly support the need to develop radio-
active neurotensin analogs for the diagnosis and therapy
of this tumor type.
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